Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group
Purpose - - Eight cycles of BEACOPPescalated (escalated dose of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by radiotherapy (RT) to initial bulk or residual tumor mass is the German Hodgkin Study Group standard of care for advanced-stage...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 11, 2011
|
| In: |
Journal of clinical oncology
Year: 2011, Volume: 29, Issue: 32, Pages: 4234-4242 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2010.33.9549 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2010.33.9549 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2010.33.9549 
|
| Author Notes: | Peter Borchmann, Heinz Haverkamp, Volker Diehl, Thomas Cerny, Jana Markova, Anthony D. Ho, Hans-Theodor Eich, Hans Konrad Mueller-Hermelink, Lothar Kanz, Richard Greil, Andreas Rank, Ursula Paulus, Lenka Smardova, Christoph Huber, Bernd Dörken, Christoph Nerl, Stefan W. Krause, Rolf-Peter Mueller, Michael Fuchs, and Andreas Engert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1805740857 | ||
| 003 | DE-627 | ||
| 005 | 20230428181848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220602s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2010.33.9549 |2 doi | |
| 035 | |a (DE-627)1805740857 | ||
| 035 | |a (DE-599)KXP1805740857 | ||
| 035 | |a (OCoLC)1341460435 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Borchmann, Peter |e VerfasserIn |0 (DE-588)107278842X |0 (DE-627)82823762X |0 (DE-576)434245321 |4 aut | |
| 245 | 1 | 0 | |a Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma |b Final analysis of the HD12 trial of the German Hodgkin Study Group |c Peter Borchmann, Heinz Haverkamp, Volker Diehl, Thomas Cerny, Jana Markova, Anthony D. Ho, Hans-Theodor Eich, Hans Konrad Mueller-Hermelink, Lothar Kanz, Richard Greil, Andreas Rank, Ursula Paulus, Lenka Smardova, Christoph Huber, Bernd Dörken, Christoph Nerl, Stefan W. Krause, Rolf-Peter Mueller, Michael Fuchs, and Andreas Engert |
| 264 | 1 | |c October 11, 2011 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.06.2022 | ||
| 520 | |a Purpose - - Eight cycles of BEACOPPescalated (escalated dose of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by radiotherapy (RT) to initial bulk or residual tumor mass is the German Hodgkin Study Group standard of care for advanced-stage Hodgkin's lymphoma (HL). However, treatment-related toxicity is a concern, and the role of RT in this setting is unclear. The HD12 study thus aimed to reduce toxicity while maintaining efficacy. - - Patients and Methods - - In this prospectively randomized multicenter trial, eight cycles of BEACOPPescalated was compared with four cycles of BEACOPPescalated followed by four cycles of the baseline dose of BEACOPP (BEACOPPbaseline; 4 + 4), and RT with no RT in the case of initial bulk or residual disease. The study was designed to exclude a difference in 5-year freedom from treatment failure (FFTF) rate of 6%. - - Results - - Between January 1999 and January 2003, 1,670 patients age 16 to 65 years were enrolled onto the HD12 study. At 5 years, FFTF was 86.4% in the BEACOPPescalated arm and 84.8% in the 4 + 4 arm (difference, −1.6%; 95% CI, −5.2% to 1.9%), and overall survival was 92% versus 90.3% (difference, −1.7%; 95% CI, −4.6% to 1.1%). Deaths related to acute toxicity of chemotherapy were observed in 2.9% of patients (BEACOPPescalated, n = 19; 4 + 4, n = 27). FFTF was inferior without RT (90.4% v 87%; difference, −3.4%; 95% CI, −6.6% to −0.1%), particularly in patients who had residual disease after chemotherapy (difference, −5.8%; 95% CI, −10.7% to −1.0%), but not in patients with bulk in complete response after chemotherapy (difference, −1.1%; 95% CI, −6.2% to 4%). - - Conclusion - - The reduction of BEACOPP to the 4 + 4 regimen did not substantially reduce severe toxicity but might decrease efficacy. Our results do not support the omission of consolidation RT for patients with residual disease. Alternative strategies for improving the risk-to-benefit ratio for patients with advanced HL are needed. | ||
| 700 | 1 | |a Haverkamp, Heinz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Diehl, Volker |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cerny, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Markova, Jana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Eich, Hans-Theodor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mueller-Hermelink, Hans Konrad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kanz, Lothar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Greil, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rank, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paulus, Ursula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Smardova, Lenka |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huber, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dörken, Bernd |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nerl, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krause, Stefan W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mueller, Rolf-Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engert, Andreas |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 29(2011), 32, Seite 4234-4242 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma Final analysis of the HD12 trial of the German Hodgkin Study Group |
| 773 | 1 | 8 | |g volume:29 |g year:2011 |g number:32 |g pages:4234-4242 |g extent:9 |a Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma Final analysis of the HD12 trial of the German Hodgkin Study Group |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2010.33.9549 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2010.33.9549 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220602 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1805740857 |e 4142489194 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Peter","display":"Borchmann, Peter","family":"Borchmann"},{"family":"Haverkamp","display":"Haverkamp, Heinz","role":"aut","given":"Heinz"},{"display":"Diehl, Volker","role":"aut","given":"Volker","family":"Diehl"},{"role":"aut","given":"Thomas","display":"Cerny, Thomas","family":"Cerny"},{"display":"Markova, Jana","given":"Jana","role":"aut","family":"Markova"},{"role":"aut","given":"Anthony Dick","display":"Ho, Anthony Dick","family":"Ho"},{"display":"Eich, Hans-Theodor","role":"aut","given":"Hans-Theodor","family":"Eich"},{"family":"Mueller-Hermelink","display":"Mueller-Hermelink, Hans Konrad","given":"Hans Konrad","role":"aut"},{"family":"Kanz","role":"aut","given":"Lothar","display":"Kanz, Lothar"},{"family":"Greil","given":"Richard","role":"aut","display":"Greil, Richard"},{"display":"Rank, Andreas","given":"Andreas","role":"aut","family":"Rank"},{"family":"Paulus","display":"Paulus, Ursula","role":"aut","given":"Ursula"},{"given":"Lenka","role":"aut","display":"Smardova, Lenka","family":"Smardova"},{"given":"Christoph","role":"aut","display":"Huber, Christoph","family":"Huber"},{"family":"Dörken","role":"aut","given":"Bernd","display":"Dörken, Bernd"},{"role":"aut","given":"Christoph","display":"Nerl, Christoph","family":"Nerl"},{"display":"Krause, Stefan W.","role":"aut","given":"Stefan W.","family":"Krause"},{"family":"Mueller","display":"Mueller, Rolf-Peter","given":"Rolf-Peter","role":"aut"},{"family":"Fuchs","given":"Michael","role":"aut","display":"Fuchs, Michael"},{"display":"Engert, Andreas","given":"Andreas","role":"aut","family":"Engert"}],"name":{"displayForm":["Peter Borchmann, Heinz Haverkamp, Volker Diehl, Thomas Cerny, Jana Markova, Anthony D. Ho, Hans-Theodor Eich, Hans Konrad Mueller-Hermelink, Lothar Kanz, Richard Greil, Andreas Rank, Ursula Paulus, Lenka Smardova, Christoph Huber, Bernd Dörken, Christoph Nerl, Stefan W. Krause, Rolf-Peter Mueller, Michael Fuchs, and Andreas Engert"]},"relHost":[{"recId":"313116962","origin":[{"dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"zdb":["2005181-5"],"issn":["1527-7755"],"eki":["313116962"]},"disp":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma Final analysis of the HD12 trial of the German Hodgkin Study GroupJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"pubHistory":["1.1983 -"],"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}],"language":["eng"],"part":{"pages":"4234-4242","extent":"9","issue":"32","text":"29(2011), 32, Seite 4234-4242","year":"2011","volume":"29"}}],"note":["Gesehen am 02.06.2022"],"physDesc":[{"extent":"9 S."}],"id":{"doi":["10.1200/JCO.2010.33.9549"],"eki":["1805740857"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1805740857","origin":[{"dateIssuedDisp":"October 11, 2011","dateIssuedKey":"2011"}],"language":["eng"],"title":[{"title":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma","subtitle":"Final analysis of the HD12 trial of the German Hodgkin Study Group","title_sort":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma"}]} | ||
| SRT | |a BORCHMANNPEIGHTCYCLE1120 | ||